

MARKET RELEASE

MedAdvisor successfully completes Placement and Institutional Entitlement offer with \$35 million to acquire US-based Adheris Health

Retail offer to open tomorrow

Melbourne, Australia, 12 November, 2020 - MedAdvisor Limited ACN 145 327 61 (ASX: MDR) (**MedAdvisor**) has successfully completed the institutional component of the accelerated non-renounceable entitlement offer (**Institutional Entitlement Offer**) and institutional placement (**Placement**) originally announced on 2 November 2020, raising approximately AUD \$35 million, exceeding the minimum required to complete the acquisition of Adheris Health.

Key highlights

- The MedAdvisor Group will become a leader in tailored opt-out, direct-to-patient medication adherence programs in the USA
- Addressable network of 180 million+ patients on an opt-out basis
- 25,000 pharmacies (>57% of prescriptions in the USA, 2.2 billion scripts p.a.)
- Network of 618,000 prescribers (~60% of total USA prescribers).
- Adheris revenue USD \$26.4 million FY20E
- Acquisition accelerates MedAdvisor's penetration in the US market by leveraging Adheris' existing pharmacy integrations reducing the need for MedAdvisor to individually integrate with the underlying US pharmacies and Electronic Health Records

The retail component of the entitlement offer (**Retail Entitlement Offer**) will open on 13 November 2020. A maximum of approximately \$20 million may be raised under the Retail Entitlement Offer any shortfall can be placed in accordance with ASX listing rules. MedAdvisor is not reliant on any amount to be raised under the Retail Entitlement Offer to complete its acquisition of Adheris Health and any funds raised will be used for ongoing working capital.

Commenting on the capital raise and acquisition of Adheris Health, MedAdvisor CEO and Managing Director Robert Read said, "This is a transformational deal for MedAdvisor which will bring digital to Adheris' enormous scale and its ability to reach 1 in 2 Americans on an opt-out basis. The additional capabilities will not only accelerate our international growth but deliver key capabilities for the expansion of our key offerings in Australia and around the world."

Adheris' strong sales pipeline of health programs relating to pharmaceuticals and vaccines built this quarter provides confidence for FY21 sales growth.

"Buying a business that we are already deeply and strategically aligned to is a tremendous value creation opportunity - especially as we continue to roll out our joint digital offering in the world's largest medicines market," Read said.

Major shareholder HMS and a number MedAdvisor directors have participated in the round. Chair

Chris Ridd's investment is subject to shareholder approval at the company's AGM on 21 December, 2020.

"The institutional component of the capital raise has seen several of our significant investors expand their positions and enabled us to welcome a number of new institutional investors to the register," Read said.

Placement and Institutional Entitlement Offer

The Placement and Institutional Entitlement Offer was supported by existing and new institutional shareholders. Approximately \$23.5 million (61,936,703 million shares) was raised under the Placement, and \$11.5 million (30,168,560 million shares) was raised under the Institutional Entitlement Offer. The shares under the Placement will be issued within MedAdvisor's Listing Rule 7.1 and 7.1A placement capacity.

Shares issued under the Placement and Institutional Entitlement Offer will be issued at the same price as the Retail Entitlement Offer (\$0.38 per share) and are expected to be allotted on 17 November 2020.

Retail Entitlement Offer

Eligible shareholders may participate in the Retail Entitlement Offer at the same price (\$0.38 per share) and offer ratio (1 new share for every 2.5 shares held) as the Institutional Entitlement Offer. Eligible shareholders' entitlements will be determined according to their ownership of shares on the record date for the Retail Entitlement Offer (7.00pm AEDT on 12 November 2020).

Further details in relation to the Retail Entitlement Offer will be provided in the retail offer booklet, to be despatched to eligible shareholders on 17 November 2020. The offer closes at 5.00pm AEDT on 1 December 2020.

Retail shareholders with questions about the Retail Entitlement Offer should call the MedAdvisor Offer Information Line on +61 2 8651 7816 between 9.00am and 4.30pm AEDT, Monday to Friday during the retail offer period (17 November 2020 to 1 December 2020).

MDR shares are expected to resume trading on ASX from market open today (12 November 2020).

Acquisition of Adheris Health

Having raised sufficient funds under the Placement and Institutional Entitlement Offer, MedAdvisor will proceed to complete the acquisition of Adheris Health, which is anticipated to complete on 17 November 2020.

"Adheris has strong, long term relationships with many of the world's major pharmaceutical companies - working with them through a suite of products which are powered by data and analytics to help engage patients and health care providers. We're very excited to combine the exemplary Adheris team with the MedAdvisor family. Their knowhow and market knowledge will help accelerate the development of medication adherence solutions for all our customers," Read said.

Timetable Update

The revised timetable issued on 10 November 2020 remains current. Section 3E.15 of the amended

Appendix 3B issued on 10 November 2020 noted the last day to extend the retail offer closing date as "27 November 2020". This should have read "26 November 2020".

The capital raising was completed by Peloton Capital.

- ENDS -

For further information, please contact:

Simon Glover
Chief Financial Officer
corporate@medadvisor.com.au
+61 3 9095 3036

Alex Beashel
Corporate Communications
ab@alexbeashel.com
+61 466 308 667

About MedAdvisor

MedAdvisor is a world-class medication management platform that empowers users to more simply manage their medication and improve adherence. MedAdvisor's highly automated and intuitive software system connects users to tools and education materials from their local/preferred pharmacy. In Australia, MedAdvisor has connected over 1.7 million users through more than 60% of Australian pharmacies and a network of thousands of GPs. MedAdvisor has partnered with HMS in the US, Zuellig Pharma in Asia and launched into the UK on track to become one of the largest players in the global digital adherence market. In 2018 and 2020, MedAdvisor was recognised in the AFR Fast 100.

Carlo Campiciano - Company Secretary
MedAdvisor Limited
(ACN 145 327 617)
Level 2
971 Burke Road
Camberwell Vic 3124